|
|
 Previous Article | Table of Contents | Next Article 
CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity
Ritsuro Suzuki,
Kazuhito Yamamoto,
Masao Seto,
Yoshitoyo Kagami,
Michinori Ogura,
Yasushi Yatabe,
Taizan Suchi,
Yoshihisa Kodera,
Yasuo Morishima,
Toshitada Takahashi,
Hidehiko Saito,
Ryuzo Ueda, and
Shigeo Nakamura
From the Department of Hematology and Chemotherapy, Department of Pathology and Clinical Laboratories, Aichi Cancer Center Hospital, Nagoya, Japan; the Laboratory of Chemotherapy and Laboratory of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan; the Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; and the Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan.
The disease spectrum of natural killer (NK) cell leukemias and lymphomas has recently been expanding with the continuing evolution in diagnostic concepts. We describe here seven cases of acute leukemia of conceivable myeloid and NK cell precursor phenotype in six men and one woman varying from 19 to 59 years of age (median, 46 years). Striking extramedullary involvement was evident at initial presentation, with peripheral lymphadenopathy and/or mediastinal masses. Two lacked any leukemic cells in the bone marrow at diagnosis. Using cytochemical myeloperoxidase staining, less than 3% of the leukemic cells showed positive reactivity. However, expression of CD7, CD33, CD34, CD56, and frequently HLA-DR, but not other NK, T-cell, and B-cell markers was observed. Cytoplasmic CD3 was detected in three of the cases by flow cytometry and in six by Northern blotting, suggesting an origin from common progenitors between the NK cell and myeloid lineages. All but one presented germline configurations of the T-cell receptor  and  chain genes and Ig heavy chain gene. With regard to morphology, the cells were generally L2-shaped, with variation in cell size, round to moderately irregular nuclei and prominent nucleoli, pale cytoplasm, and a lack of azurophilic granules. Histopathologic examination of biopsied specimens of extramedullary tumors showed a lymphoblast-like morphology, implying the differential diagnostic problem from lymphoblastic lymphomas, especially in cases lacking bone marrow involvement. Three patients were successfully treated with chemotherapy for acute myeloid leukemia (AML), whereas three other patients proved refractory to chemotherapeutic regimens for lymphoid malignancies, although two responded to subsequent AML chemotherapy. However, despite intensive chemotherapy, including allogeneic bone marrow transplantation, most persued fatal courses within 41 months. These data suggested that the CD7+ and CD56+ myeloid/NK cell precursor acute leukemia might constitute a distinct biologic and clinical disease entity. Its recognition appears to be particularly important for the clinicopathologic evaluation of CD56+ hematolymphoid malignancies and the development of therapeutic approaches to such disease.
Blood, Vol. 90 No. 6 (September 15), 1997:
pp. 2417-2428
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Assaf, S. Gellrich, S. Whittaker, A. Robson, L. Cerroni, C. Massone, H. Kerl, C. Rose, A. Chott, S. Chimenti, et al.
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer
J. Clin. Pathol.,
September 1, 2007;
60(9):
981 - 989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sconocchia, H. Fujiwara, K. Rezvani, K. Keyvanfar, F. El Ouriaghli, M. Grube, J. Melenhorst, N. Hensel, and A. J. Barrett
G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte
J. Leukoc. Biol.,
December 1, 2004;
76(6):
1214 - 1219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Audouin, E. Comperat, A. L. Tourneau, S. Camilleri-Broet, C. Adida, T. Molina, and J. Diebold
Myeloid Sarcoma: Clinical and Morphologic Criteria Useful for Diagnosis
International Journal of Surgical Pathology,
October 1, 2003;
11(4):
271 - 282.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Perez, P. A. Sotiropoulou, D. G. Gkika, L. G. Mahaira, D. K. Niarchos, A. D. Gritzapis, Y. G. Kavalakis, A. I. Antsaklis, C. N. Baxevanis, and M. Papamichail
A novel myeloid-like NK cell progenitor in human umbilical cord blood
Blood,
May 1, 2003;
101(9):
3444 - 3450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ogata, K. Nakamura, N. Yokose, H. Tamura, M. Tachibana, O. Taniguchi, R. Iwakiri, T. Hayashi, H. Sakamaki, Y. Murai, et al.
Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome
Blood,
December 1, 2002;
100(12):
3887 - 3896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Feuillard, M.-C. Jacob, F. Valensi, M. Maynadie, R. Gressin, L. Chaperot, C. Arnoulet, F. Brignole-Baudouin, B. Drenou, E. Duchayne, et al.
Clinical and biologic features of CD4+CD56+ malignancies
Blood,
March 1, 2002;
99(5):
1556 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yamaguchi, M. Seto, M. Okamoto, R. Ichinohasama, N. Nakamura, T. Yoshino, J. Suzumiya, T. Murase, I. Miura, T. Akasaka, et al.
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
Blood,
February 1, 2002;
99(3):
815 - 821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Meech, L. McGavran, L. F. Odom, X. Liang, L. Meltesen, J. Gump, Q. Wei, S. Carlsen, and S. P. Hunger
Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion
Blood,
August 15, 2001;
98(4):
1209 - 1216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone, D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, M. R. Baer, et al.
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
Blood,
August 1, 2001;
98(3):
548 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood,
November 1, 2000;
96(9):
2993 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yatabe, R. Suzuki, K. Tobinai, Y. Matsuno, R. Ichinohasama, M. Okamoto, M. Yamaguchi, J.-i. Tamaru, N. Uike, Y. Hashimoto, et al.
Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
Blood,
April 1, 2000;
95(7):
2253 - 2261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ferrara, F. Morabito, B. Martino, G. Specchia, V. Liso, F. Nobile, P. Boccuni, R. Di Noto, F. Pane, M. Annunziata, et al.
CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1295 - 1300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cools, C. Bilhou-Nabera, I. Wlodarska, C. Cabrol, P. Talmant, P. Bernard, A. Hagemeijer, and P. Marynen
Fusion of a Novel Gene, BTL, to ETV6 in Acute Myeloid Leukemias With a t(4;12)(q11-q12;p13)
Blood,
September 1, 1999;
94(5):
1820 - 1824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd
CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?
J. Clin. Oncol.,
January 1, 1999;
17(1):
293 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kimura, T. Yoshida, M. Nagano, K. Tamura;, R. Suzuki, M. Seto, Y. Morishima, and S. Nakamura
Importance of T-Cell Receptor delta -Chain Gene Analysis on CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia
Blood,
April 1, 1998;
91(7):
2622 - 2624.
[Full Text]
[PDF]
|
|
|
|
|
